哈药股份：全资子公司拟4480万元购买达普司他片临床批件

Group 1 - The core point of the article is that Harbin Pharmaceutical Group Co., Ltd. plans to purchase the clinical approval for Dapoxetine tablets for a total amount of 44.8 million yuan through its wholly-owned subsidiary [1] - The contract will be signed with Shanghai Bozhi Research and Development Co., Ltd. for technology transfer and subsequent development and marketing cooperation [1] - This transaction does not constitute a related party transaction or a major asset restructuring, and it does not require approval from the shareholders' meeting [1] Group 2 - The pharmaceutical development cycle is long and carries significant risks, with uncertainties at various stages [1]